Analysts on Wall Street project that Bally's (BALY) will announce quarterly loss of -$0.71 per share in its forthcoming report, representing an increase of 64.3% year over year. Revenues are projected to reach $659.65 million, increasing 4.7% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings anno ...

Wall Street analysts expect American Healthcare REIT (AHR) to post quarterly earnings of $0.42 per share in its upcoming report, which indicates a year-over-year increase of 16.7%. Revenues are expected to be $565.26 million, up 7.9% from the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a company reveals its earnings ...

The upcoming report from Curtiss-Wright (CW) is expected to reveal quarterly earnings of $3.28 per share, indicating an increase of 10.4% compared to the year-ago period. Analysts forecast revenues of $871.92 million, representing an increase of 9.1% year over year.The consensus EPS estimate for the quarter has been revised 0.6% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Befo ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - Omega Healthcare Investors (OHI) reported quarterly funds from operations (FFO) of $0.79 per share, exceeding the Zacks Consensus Estimate of $0.77 per share and up from $0.74 per share a year ago [1][2] - The company achieved an FFO surprise of +2.60% for the quarter, having surpassed consensus FFO estimates three times over the last four quarters [2] - Revenues for the quarter ended September 2025 were $311.59 million, surpassing the Zacks Consensus Estimate by 0.97% and up from $276.03 million year-over-year [3] Financial Performance - The FFO for the previous quarter was $0.77, which also beat the expected $0.75, resulting in a surprise of +2.67% [2] - The current consensus FFO estimate for the upcoming quarter is $0.78, with projected revenues of $310.44 million, and for the current fiscal year, the estimate is $3.07 on $1.18 billion in revenues [8] Market Position - Omega Healthcare Investors has underperformed the market with a gain of about 4.4% since the beginning of the year, compared to the S&P 500's gain of 17.2% [4] - The Zacks Industry Rank places the REIT and Equity Trust - Other sector in the top 34% of over 250 Zacks industries, indicating a favorable industry outlook [9] Future Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future FFO expectations [4] - The estimate revisions trend for Omega Healthcare Investors was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it will perform in line with the market [7]

Core Insights - Cardinal Health, Inc. reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.55, exceeding the Zacks Consensus Estimate of $2.21 by 15.4%, and showing a year-over-year improvement of 35.6% [1][8] - Total revenue for the quarter reached $64 billion, marking a 22% increase year over year and surpassing the Zacks Consensus Estimate by 8.4% [2][8] Revenue Details - Sales increased by 22% year over year to $64 billion, beating estimates [2] Segmental Analysis - **Pharmaceutical and Specialty Solutions**: Revenues rose 23% to $59.2 billion, driven by growth in branded and specialty pharmaceutical sales [3] - **Pharmaceutical Profit**: Totaled $667 million, up 26% from the previous year, supported by brand and specialty products [4] - **Global Medical Products and Distribution**: Revenues reached $3.2 billion, a 2% increase year over year, with profits rising from $8 million to $46 million [4] - **Other Segment**: Sales grew 38% to $1.6 billion, with profits increasing 60% to $166 million, driven by strong performance across its operating segments [5] Margin Analysis - Gross profit increased 22% year over year to $2.32 billion, with a gross margin of 3.6% [6] - Distribution, selling, general and administrative expenses rose 14% to $1.46 billion [6] - Operating income was $668 million, an 18% increase year over year, with adjusted operating income up 37.1% to $857 million [6] Financial Update - The company ended the quarter with cash and cash equivalents of $4.59 billion, up from $3.87 billion in the previous quarter [9] - Net cash provided by operating activities was $973 million, compared to $1.65 billion used in the same period last year [9] 2026 Outlook - Cardinal Health raised its fiscal 2026 earnings guidance, expecting adjusted EPS between $9.65 and $9.85, up from a prior outlook of $9.30-$9.50 [10] - Projected revenue growth for the Pharmaceutical segment is 11-13%, with segment profit expected to increase 16-19% [10][11] - Medical segment revenues are estimated to grow 2-4%, while the Other segment is expected to see revenue growth of 26-28% [11] Conclusion - The company reported strong first-quarter results, with broad-based profit growth across all segments, particularly in Pharmaceutical and Specialty Solutions [12] - The positive results led to a 10% increase in shares during pre-market trading, with a year-to-date gain of 39.1% compared to the industry’s 4.1% [13]

Axis Mutual Fund says the long streak of downgrades in India’s earnings estimates may finally be coming to an end, after the trend left the South Asian nation trailing its global peers https://t.co/k2HxLl5JUW ...

Core Insights - ServiceNow projects Q3 EPS at 4.27 with revenue expected to reach 3.36 billion, indicating strong financial performance [1] - For the fiscal year 2025, the company anticipates an EPS of 16.89, suggesting growth potential in the coming years [1] Financial Projections - Q3 EPS estimate: 4.27 [1] - Q3 revenue estimate: 3.36 billion [1] - FY 2025 EPS estimate: 16.89 [1]

Group 1 - Clover Health Investments, Corp. (NASDAQ:CLOV) experienced a significant stock price increase of 19.37% on a recent Friday, closing at $3.82 per share, driven by a "buy" recommendation from Zacks Research [1] - Zacks Research upgraded Clover Health to "buy" due to an upward trend in earnings estimates, which is a critical factor influencing stock prices [1] - For the fiscal year ending December 2025, Clover Health is projected to earn $0.10 per share, consistent with the previous year's reported figure, while analysts have raised their earnings estimates by 25% over the past three months [2] Group 2 - Clover Health is expected to release its third quarter financial and operating highlights on November 6, 2025, based on historical reporting dates [3]

Key Takeaways Dover reported Q3 adjusted EPS of $2.62, topping estimates and rising from $2.27 a year ago.Revenues grew 4.8% to $2.08B, while gross margin improved to 40.1% from 38.5% last year.Strong demand led Dover to raise its 2025 EPS guidance to $9.50-$9.60, up from $9.35-$9.55.Dover Corporation (DOV) has reported third-quarter 2025 adjusted earnings per share (EPS) from continuing operations of $2.62, beating the Zacks Consensus Estimate of $2.50. In the year-ago quarter, the company reported an adju ...